ScoreWhy is ImmunityBio, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -206.85% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -38.35
2
With a growth in Operating Profit of 20.85%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -319.7 MM
- NET SALES(Q) Highest at USD 32.06 MM
- OPERATING PROFIT MARGIN(Q) Highest at -161.19 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 201.42%, its profits have risen by 24.2%
4
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 5.39% over the previous quarter and collectively hold 19.88% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ImmunityBio, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ImmunityBio, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
ImmunityBio, Inc.
234.52%
0.33
107.14%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
142.27%
EBIT Growth (5y)
-206.85%
EBIT to Interest (avg)
-38.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.23
Sales to Capital Employed (avg)
0.08
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.88%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-16.10
EV to EBIT
-34.56
EV to EBITDA
-36.79
EV to Capital Employed
201.43
EV to Sales
109.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-582.85%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend32What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -319.7 MM
NET SALES(Q)
Highest at USD 32.06 MM
OPERATING PROFIT MARGIN(Q)
Highest at -161.19 %
RAW MATERIAL COST(Y)
Fallen by -230.72% (YoY
CASH AND EQV(HY)
Highest at USD 411.47 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 4.47 times
OPERATING PROFIT(Q)
Highest at USD -51.68 MM
PRE-TAX PROFIT(Q)
Highest at USD -81.34 MM
NET PROFIT(Q)
Highest at USD -81.28 MM
EPS(Q)
Highest at USD -0.07
-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for ImmunityBio, Inc.
Net Sales
At USD 32.06 MM has Grown at 126.58%
over average net sales of the previous four periods of USD 14.15 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 32.06 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -161.19 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Operating Cash Flow
Highest at USD -319.7 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -51.68 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -81.34 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -81.28 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.07
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 411.47 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 4.47 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -230.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
